Back to search results

Antidepressant Therapy for Blood Vessel Health After Preeclampsia

This study is looking at how two treatments, Paroxetine Hydrochloride (an antidepressant) and Ascorbic acid (Vitamin C), affect blood vessel health in women after pregnancy. Women who had preeclampsia (high blood pressure during pregnancy) or depression, or both, are more likely to have heart problems later. Researchers believe this might be due to changes in their blood vessels. This study will deliver these treatments directly to small blood vessels in the skin to see if they improve how well these vessels expand. You may be able to join if you are a woman between 18 and 45 years old, 12 weeks to 5 years after pregnancy, with or without a history of preeclampsia or depression. The study aims to enroll 40 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 40 women.
What's involved
The primary endpoints are measured at the study visit, which averages 4 hours. This suggests a single visit or a short series of visits.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints are measured at the study visit, an average of 4 hours, suggesting follow-up is limited to this visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07715669

Antidepressant Therapy for Improved Blood Vessel Health After Preeclampsia

Recruiting
EARLY_PHASE1Ages 18–45InterventionalBasic science
Anna Stanhewicz, PhD
~40 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:Paroxetine HydrochlorideAscorbic acid (Vitamin C)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Microvascular endothelium-dependent dilation response measured by laser-Doppler flowmetry
Measured over at the study visit, an average of 4 hours
+1 more outcome measured

Conditions

Preeclampsia
Endothelial Function

Explore related trials

DepressionPreeclampsia

Where it's being run

1 sites across 1 states
Iowa1

Who to contact

Anna Reid-Stanhewicz, PHD
[email protected]
319-467-1732
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18-24 years old,
12 weeks - 5 years post pregnancy
one of the following:
history of a normal pregnancy with a current diagnosis of depression,
history of a normal pregnancy without a current diagnosis of depression,
history of a preeclamptic pregnancy with a current diagnosis of depression
history of preeclamptic pregnancy without a current diagnosis of depression.

Exclusion

history of cardiovascular, metabolic, and/or skin diseases
current or history of tobacco/nicotine/ e-cigarette use
history of gestational diabetes
current antihypertensive or cholesterol-lowering medication
currently pregnant
allergy to materials used during the experiment (e.g. latex),
known allergy to study drugs
currently using SSRI medications

What this trial measures

  • Microvascular endothelium-dependent dilation response measured by laser-Doppler flowmetryat the study visit, an average of 4 hours

    Cutaneous vascular conductance responses to local heating over a microdialysis fiber receiving treatments compared to lactated Ringer's solution (control).

  • Nitric oxide-dependent dilation response measured by laser-Doppler flowmetryat the study visit, an average of 4 hours

    Difference in cutaneous vascular conductance between local heating plateau and post-L-NAME plateau within each treated microdialysis site compared to lactated Ringer's (control).